<DOC>
	<DOCNO>NCT00576433</DOCNO>
	<brief_summary>This single arm study evaluate safety efficacy MabThera patient active rheumatoid arthritis receive methotrexate treatment , inadequate response one anti-TNF alpha therapy . All patient receive MabThera 1000mg i.v . day 1 15 , addition concomitant methotrexate . Patients achieve clinically relevant response first course treatment may eligible receive one re-treatment course MabThera week 24 48 . The anticipated time study treatment 3-12 month , target sample size 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Single Anti-TNF Inhibitor .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , 1880 year age ; moderate severe active rheumatoid arthritis ; inadequate response previous current treatment 1 antiTNF agent ; receive methotrexate dose 1025mg/week 12 week prior start study , stable dose &gt; =4 week . previous treatment MabThera ; use antiTNF alpha agent within 8 week study start ; concurrent treatment DMARD methotrexate ; active infection , history serious recurrent chronic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>